Therapeutics: MAP kinase kinase kinase kinase 3 (MAP4K3; GLK); kruppel-like factor 2 (KLF2); kruppel-like factor 4 (KLF4; EZF)

Cardiovascular disease

INDICATION: Cardiovascular

Patient sample and mouse studies suggest inhibiting the MAP4K3-KLF2/KLF4 pathway could help treat cerebral cavernous malformations

Read the full 183 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE